Evrima

Evrima Technologies operates as a specialized technology platform focused on optimizing the clinical trial process for participants, researchers, and clinicians. The company was established in 2018 by Charlotte Bradshaw, who now serves as the CEO. Bradshaw's decade of prior experience within the clinical trial sector provided the foundational insights for developing solutions to improve recruitment and trial management.

The firm's business model centers on connecting a diverse range of trial participants with medical researchers and clinicians to streamline recruitment and management. It addresses the significant challenge of patient recruitment, which is a major cost and cause of delays in the development of new drugs and therapies. Evrima generates revenue by providing its technology-driven tools and services to sponsors, contract research organizations (CROs), and clinical trial sites. A key operational strategy involves integrating its platform with general practitioner (GP) clinics, which are often the first point of contact for patients, thereby expanding the accessible patient pool for trials. In May 2024, the company announced a successful pilot project in New South Wales, Australia, that integrated GP, pharmacy, and clinical trial site networks to identify and refer eligible participants.

Evrima's suite of products includes three core offerings. 'Evrilink' is a clinical trial recruitment platform that allows trial site users to manage the enrollment process, track participant progress, and automate communications. It also serves as a portal for participants to register interest and manage their documentation. 'Evripath' is a search tool designed for General Practitioners and other healthcare professionals to find and refer patients to suitable clinical trials. This tool integrates with practice management software to simplify the process. Finally, 'Evriquest' comprises tailored clinical trial recruitment services designed to find the right participants for specific trials.

Financially, Evrima has secured a total of $3 million in funding through a single Seed round that took place on September 5, 2022. The round was led by Artesian and included other institutional investors such as BridgeLane. Keywords: clinical trial recruitment, patient recruitment, clinical trial management, health-tech, med-tech, participant engagement, clinical research solutions, trial site network, CRO services, sponsor solutions, GP referral platform, Charlotte Bradshaw, Evrilink, Evripath, Evriquest, Artesian, BridgeLane, clinical trial software, medical research, patient identification, eRecruitment, trial matching, healthcare technology, Australian startup